Literature DB >> 15235853

Prevention of hypertensive crisis with ATP during anesthesia for pheochromcytoma.

K Murata1, O Sodeyama, K Ikeda, A F Fukunaga.   

Abstract

In the anesthetic management of five patients undergoing excision of pheochromocytoma, adenosine triphosphate (ATP) was used for the purpose of regulating systemic arterial pressure during the period of tumor manipulation. ATP was administered at doses of 0.05-0.4 mg/kg/min. Systemic arterial pressure showed a significant decrease from 162 +/- 17/103 +/- 11 mmHg before manipulation to 136 +/- 21/81 +/- 10 mmHg during the manipulation period. The plasma catecholamine levels showed significant increases in this period. Immediately after excision, the systemic arterial pressure was maintained at normal levels (118 +/- 13/75 +/- 16 mmHg) by fluid replacement and discontinuation of ATP administration, subsequently becoming 129 +/- 19/79 +/- 16 mmHg. The heart rate was very stable and tachycardia did not occur during the manipulation period. Only one arrhythmic episode occurred in one patient. The systemic vascular resistance index was significantly lower during the manipulation period than before it. It was therefore considered that ATP was useful as an agent for controlling arterial pressure during the anesthesia for pheochromocytoma.

Entities:  

Year:  1987        PMID: 15235853     DOI: 10.1007/s0054070010162

Source DB:  PubMed          Journal:  J Anesth        ISSN: 0913-8668            Impact factor:   2.078


  12 in total

1.  Adenosine as inhibitor of myocardial effects of catecholamines.

Authors:  J Schrader; G Baumann; E Gerlach
Journal:  Pflugers Arch       Date:  1977-11-25       Impact factor: 3.657

2.  Use of alpha and beta adrenergic blocking drugs and halothane in the anaesthetic management of phaeochromocytoma.

Authors:  D M Gebbie; D C Finlayson
Journal:  Can Anaesth Soc J       Date:  1967-01

3.  Anaesthetic management of patients with phaeochromocytoma. A review of 102 cases.

Authors:  J M Desmonts; J le Houelleur; P Remond; P Duvaldestin
Journal:  Br J Anaesth       Date:  1977-10       Impact factor: 9.166

Review 4.  Modulation of neurotransmission by purine nucleotides and nucleosides.

Authors:  B B Fredholm; P Hedqvist
Journal:  Biochem Pharmacol       Date:  1980-06-15       Impact factor: 5.858

Review 5.  Anaesthetic management of patients with phaeochromocytoma.

Authors:  J M Desmonts; J Marty
Journal:  Br J Anaesth       Date:  1984-07       Impact factor: 9.166

6.  Anesthetic management of pheochromocytoma employing halothane and beta adrenergic blockade. A report of fourteen cases.

Authors:  L H Cooperman; K Engelman; P E Mann
Journal:  Anesthesiology       Date:  1967 May-Jun       Impact factor: 7.892

7.  Hypotensive effects of adenosine and adenosine triphosphate compared with sodium nitroprusside.

Authors:  A F Fukunaga; W E Flacke; B C Bloor
Journal:  Anesth Analg       Date:  1982-03       Impact factor: 5.108

8.  Antiarrhythmic and hemodynamic responses to adenosine triphosphate during infusion of epinephrine in dogs anesthetized with halothane.

Authors:  Y Z Sohn; J C Hong; R L Katz
Journal:  Anesth Analg       Date:  1982-05       Impact factor: 5.108

9.  Inhibition of sympathetic neurotransmission in canine blood vessels by adenosine and adenine nucleotides.

Authors:  R H Verhaeghe; P M Vanhoutte; J T Shepherd
Journal:  Circ Res       Date:  1977-02       Impact factor: 17.367

10.  Controlled hypotension with adenosine in cerebral aneurysm surgery.

Authors:  A Sollevi; M Lagerkranser; L Irestedt; E Gordon; C Lindquist
Journal:  Anesthesiology       Date:  1984-10       Impact factor: 7.892

View more
  2 in total

1.  Influence of tumor size on anesthetic management for pheochromocytoma resection.

Authors:  Matsuyuki Doi; Kazuyuki Ikeda
Journal:  J Anesth       Date:  1994-12       Impact factor: 2.078

2.  Comparative cardiovascular effects of SNP, ATP and phentolamine during norepinephrine-induced hypertension in dogs.

Authors:  K Murata; H Takahashi; K Ikeda
Journal:  J Anesth       Date:  1991-10       Impact factor: 2.078

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.